Thrombotic microangiopathy after bone marrow transplantation (post-BMT TMA) is a serious transplantrelated complication. We identified 16 patients with TMA after allogeneic BMT who showed histopathological evidence of intestinal TMA in their gut specimens (six autopsies, 10 biopsies). In all, 14 patients had grade II-IV acute graft-versus-host disease (GVHD). The first seven patients were retrospectively diagnosed with TMA. Since six of them were diagnosed with progressive GVHD at that time because there was no awareness of the existence of intestinal TMA, they received more intensive treatment for GVHD, but all died between days þ 49 and þ 253. In contrast, the remaining nine patients were recently diagnosed with intestinal TMA on the basis of colonoscopic biopsies. For eight of these patients, the immunosuppressants were reduced, and the patients' intestinal symptoms improved gradually. Six of the nine patients were still alive 12 months after the diagnosis of TMA. Our findings suggest that the gut may be a site involved in post-BMT TMA, presenting as ischemic enterocolitis. Differentiating intestinal TMA from acute GVHD is important in patients suffering from severe and refractory diarrhea after BMT.
geneic bone marrow transplantation; graft-versus-host disease; bloody diarrhea; colonoscopic biopsy Thrombotic microangiopathy (TMA) is a well-recognized disorder that occurs after either allogeneic or autologous bone marrow transplantation (BMT). [1] [2] [3] [4] Although several factors may contribute to the onset of this complication, acute graft-versus-host disease (GVHD), cyclosporin A (CsA), tacrolimus (FK506), total body irradiation (TBI), high-dose chemotherapy and infection play a critical role in its etiology. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] As TMA is associated with high mortality, its early diagnosis is particularly important. A grading system (grades 0-4) of TMA based on two clinical parameters, lactic dehydrogenase (LDH) level and the percentage of fragmented erythrocytes, 2 has been proposed for this purpose. However, it is often difficult to diagnose TMA in patients who have undergone BMT due to the heterogeneity of TMA.
In previous studies on post-BMT TMA, much attention has been paid to renal impairment and central nervous system toxicity, but far less to the potential involvement of the target organs for acute GVHD. It is well known, however, that gastroenteritis accompanied by bloody diarrhea and abdominal pain often heralds the onset of renal failure in young children with classical hemolytic uremic syndrome (HUS). Recent pathological studies have shown the presence of microangiopathy in the intestinal mucosa of patients with HUS associated with Escherichia coli O157:H7 infections. 17, 18 Moreover, thrombotic thrombocytopenic purpura (TTP) not related to BMT is characterized by disseminated platelet thrombosis in the microvasculature of multiple organs including the intestinal tract, liver and skin. 19 Therefore, it seems reasonable to assume that the gut may be involved in microangiopathy in patients with the florid form of post-BMT TMA.
For the study presented here, we identified 16 cases with histopathological evidence of post-BMT TMA. This report is the first to show that the intestine can be involved in TMA following BMT.
Materials and methods

Patients
Between 1987 and 1999, 251 patients underwent allogeneic BMT at the Department of Internal Medicine, Japanese Red Cross Nagoya First Hospital. Of these patients, 16 showed pathological evidence of intestinal TMA (six by autopsy, 10 by biopsy). The 16 patients' records were retrospectively examined. All patients gave written informed consent for participation in these treatments.
BMT procedures
Several preparative regimens were employed for the allogeneic BMT patients (Table 1) . Oral busulfan (BU) 4 mg/kg/day was administered for 2 days (days À7, À6) followed by intravenous (i.v.) cyclophosphamide (CY) 60 mg/kg by 3-h i.v. infusion for 2 days (days À5, À4) and by 5 Gy of TBI given daily for 2 days (days À2, À1). Cytosine arabinoside (CA) 2 g/m 2 was administered by 3-h i.v. infusion for 3 days (days À6 ( Â 2), À5, À4) followed by CY 60 mg/kg for 2 days (days À5, À4) and by TBI 6 Gy daily for 2 days (days À2, À1). Melphalan (LPAM) 60 mg/ m 2 was administered by a one-shot i.v. infusion for 3 days (days À6, À5, À4) followed by TBI 5 Gy daily for 2 days (days À2, À1). Patients 3 and 5 received chemotherapy, comprising carboplatin and CA or mitoxantron, etoposide and CA, to reduce their tumor burden 14 days before the preconditioning.
GVHD prophylaxis for seven patients consisted of a combination of i.v. methotrexate (MTX) at 10 mg/m 2 on day 1 and at 7 mg/m 2 on days 3 and 5 and i.v. CsA at 3 mg/ kg/day beginning on day À1. GVHD prophylaxis of the remaining nine patients comprised a combination of MTX and continuous i.v. tacrolimus (FK506) at 0.03 mg/kg/day beginning on day À1.
Corticosteroids were administered once acute GVHD (more than grade II) had been diagnosed according to the following schedule: methylprednisolone (mPSL) at 20 mg/ kg i.v. for 3 days, at 15 mg/kg for 3 days and then tapered off. mPSL 2-4 mg/kg i.v. for 7-14 days was administered simultaneously with FK506 depending on disease severity when acute GVHD (Xgrade II) had been identified in the more recent six patients.
Colonoscopic examination
Of 122 patients who received BMT after 1996, 10 underwent colonoscopic examination together with mucosal biopsy to determine the etiology of severe and refractory bloody diarrhea. An intermediate length scope (CF200I; Olympus, Tokyo, Japan) was used for this examination.
Histopathological and immunohistological study
Biopsy specimens were obtained from 10 patients who were suffering from at least 500 ml/day of bloody diarrhea after allogeneic BMT. Five or six specimens including those of the cecum were obtained from nine of these patients, and three specimens from the rectum of the remaining patient who underwent retrosigmoidoscopy only. The autopsy specimens obtained from six patients who had developed bloody diarrhea (500 ml/day) after allogeneic BMT were also analyzed. All tissues were fixed in 10% formalin, embedded in paraffin and stained with hematoxylin-eosin (HE) and elastica van Gieson. Serial sections were used for biopsy materials. For autopsy materials, seven or more tissue samples were taken from the affected parts of the intestine and mounted on cardboard to avoid flection. A minimum of three blocks was cut from each sample.
Immunostaining of representative sections used monoclonal antibodies for GPIIbIIIa (CD41a), von Willebrand factor (vWF), CD34, a-smooth muscle actin (a-SMA) and cytomegalovirus (CMV). Pathological specimens were reviewed in a blinded manner.
Diagnosis of TMA
Diagnosis of TMA was histologically based on either hyaline (platelet) thrombi in the capillaries of the biopsy specimens or thrombonecrotic arteriolar lesions (thrombonecrotic arteriolopathy) of the intestine in the autopsy specimens. TMA was also clinically diagnosed according to the grading system for BMT-TMA, which is based on the LDH level and the proportion of fragmented erythrocytes as described previously. 2 A single observer counted 500 red blood cells on blinded smears and calculated the percentage of fragmented erythrocytes retrospectively. A fragmented erythrocyte was defined as a schistocyte (crescent, helmet or triangle) 2, 20 and the LDH/platelet ratio as described previously. 2 
Diagnosis of GVHD
Acute GVHD was diagnosed and graded from I to IV on the basis of the consensus criteria 21 for each of the clinical sites. The clinical and laboratory parameters used to assess the grade of acute GVHD included the percentage of bodysurface area with skin rash, the volume of diarrhea, total bilirubin and Karnofsky's performance status. Skin biopsy samples were obtained to confirm the diagnosis of acute GVHD before the start of treatment for 14 patients. Gut biopsies were obtained from nine patients during the treatment for acute GVHD. Patients surviving beyond day 100 were considered to qualify as chronic GVHD, which was categorized as limited type (localized skin and/or hepatic involvement) or extensive type (diffuse skin and/or multiorgan involvement). 22 
Results
Patient characteristics
The 16 patients with pathological evidence of intestinal TMA consisted of three females and 13 males with a median age of 39 (range: 20-49) years. Pre-transplantation, all patients showed normal organ functions. Patient background characteristics are listed in Table 1 . Four of the 16 patients had undergone ABO compatible transplantation. However, four patients (3, 6, 9 and 15) underwent majorminor, two (7 and 16) major and six (1, 2, 5, 8, 13 and 14) minor ABO-mismatched transplantations, respectively. Two patients (1 and 8) underwent transplantation from a phenotypically identical related donor and four (3, 4, 5 and 12) from a HLA-A-, -B-, DRB1-matched unrelated donor. The remaining 10 patients received class I or II DNAmismatched or serologically mismatched unrelated donor transplants. Their diagnoses consisted of chronic myelogenous leukemia (eight), acute myelocytic leukemia (three), acute lymphoblastic leukemia (two), and one each for adult T-cell leukemia, non-Hodgkin's lymphoma and myelodysplastic syndrome.
Clinical and laboratory findings of TMA patients
The clinical findings and blood examinations for the TMA patients are shown in Table 2 . Clinically, 14 of the 16 patients were diagnosed with multifactorial TMA. TMA onset ranged from days þ 16 to þ 69 after BMT. Four patients had grade 4, six had grade 3 and four had grade 2 BMT-TMA. The median peak of the percentage of fragmented erythrocytes was 6.7% with a range of 0.8-13.3%. The median peak LDH level was 879 IU/l (range, 382-2274 IU/l), which was twice as high as the upper range of normal laboratory findings. All patients clinically diagnosed with TMA also showed other findings of microangiopathic hemolytic anemia: reticulocytosis, refractory thrombocytopenia or a low haptoglobin level.
Stool specimens were routinely obtained from all patients and cultured for the presence of bacterial and fungal Normal range : peak % fragmented erythrocytes ¼ o1.2%; peak LDH ¼ o500 IU/l; Hpt ¼ haptoglobin.
Intestinal TMA after allogeneic BMT T Nishida et al pathogen. Staphylococcus epidermidis was detected in the stool obtained from 13 patients, and Bacteroides was detected from two patients. These pathogens were also detected after the intestinal symptoms improved due to the reduction of immunosuppressants, as well as during diarrhea. S. aureus, which was sensitive to antibiotics, was detected once in three examinations during diarrhea from patient 12. Candida glabrata was also detected once in six examinations during diarrhea from patient 16. The pathogens that cause enterocolitis, such as Clostridium difficile, Salmonella, Shigella, Campylobacter, E. coli O157:H7, were not detected. Isolation of viral pathogens was performed for stool specimens obtained from 11 patients during diarrhea, but no viral pathogens were isolated. These results suggest that the pathogens detected in this study did not cause diarrhea directly.
Clinical symptoms and outcome
All 16 patients developed severe bloody diarrhea (910-3400 ml/day). Of the 15 patients who could be evaluated, 14 (93%) had grade II-IV acute GVHD. They were treated with mPSL 1 g pulse therapy or mPSL 2-4 mg/kg i.v. against the advancement of acute GVHD. Antithymocyte globulin was also given to five patients as tertiary treatment.
The initial seven patients were diagnosed post mortem with TMA. Six of these patients (1, 2, 4, 5, 6 and 7) had severe bloody diarrhea, which was thought to be caused by the recurrence of acute enteric GVHD at that time. They therefore received more intensive immunosuppressive therapy, but all died between days þ 49 and þ 253. Two died from veno-occlusive disease (VOD), one each from renal failure due to nephritis, multiple organ failure (MOF), drug-induced encephalopathy and suicide. Three patients (2, 4 and 5) underwent therapeutic apheresis with plasma exchange, but none of them responded. Another patient, who was diagnosed with TMA by autopsy, suffered from cerebral bleeding and died on day þ 24.
The next nine patients (8-16) were diagnosed as TMA from the results of gut biopsy. Bloody diarrhea and abdominal pain continued in patients 9-16 even after improvement of acute GVHD of skin. Immunosuppressants were reduced and the patients' intestinal symptoms improved gradually. Antibiotics were administered to four patients (8, 9, 10 and 16) who had the episodes of fever during diarrhea, but there was no relation between their courses of fever and diarrhea. In patient 8, immunosuppressive agents could not be reduced because of the severity of GVHD grade IV, and he died of VOD and liver failure on day þ 83. Six of these nine patients (67%) were still alive 12 months after the diagnosis of TMA. Three patients (10, 15 and 16) are alive and well 68, 44 and 42 months post transplantation. Table 3 summarizes the outcome.
Six (75%) of eight patients who could be evaluated developed chronic GVHD (five extensive type and one limited type). One patient (12) suffered from bloody diarrhea again after chronic GVHD improved with the administration of corticosteroids, and he died on day þ 473. In two patients (9 and 11), chronic GVHD progressed in spite of immunosuppressive therapy and they died of chronic GVHD and respiratory failure on days þ 1020 and þ 1098.
Patient 13 and 14 died of liver failure and MOF, respectively, even though their diarrhea due to intestinal TMA improved with the tapering of the immunosuppressive agents.
Colonoscopic findings
Colonoscopic examination was performed for 10 of the recent patients (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . Their mucosa was edematous and erosive, and they showed multiple irregular erythemas with spontaneous bleeding in the rectum. Similar lesions were observed in the sigmoid and transverse colon. Interestingly, these findings were more severe in the cecum.
Histopathological and immunohistological findings
Microangiopathy was identified in all 16 patients. Postmortem angiopathy was predominantly found in the submucosal arterioles as either thrombonecrosis or mucoid subintimal thickening. However, the small intestine of patient 3, who had died on day þ 24 post-BMT, showed only mucosal changes. There were fibrinoid necrosis of the terminal arterioles located in deep mucosa, extravasation with red cell fragmentation around the affected vessels, extensive crypt depletion and hemorrhage in the tip of mucosal folds.
As for the biopsy specimens, the vascular changes in the mucosa were subtle. Various degrees of perivascular hemorrhages with or without hemosiderin were commonly observed (Figure 1a) . Careful examination of serial sections turned up a few capillary thrombosis either granular or hyaline in appearance (Figure 1b) . The thrombi were confirmed as platelet thrombi by immunostaining with CD41a ( Figure 1c ) and vWF. Immunohistochemistry with CD34 and a-SMA showed a decrease in the staining intensity of the affected vessels (data not shown). Diagnostic changes in patient 7, 8, 10 and 11 were present only in the cecal mucosa. These histologic features were frequent in the specimens taken from erosive mucosa composed of crypt depletion and hemorrhage. A few CMV inclusion cells were found in the specimens of three patients (8, 9 and 13). The findings of enterocolitis due to bacterial and fungal infection were not found. Although exploding crypt lesions suggestive of GVHD were seen in several of the regenerating mucosa of the other two patients (11 and 12), it was difficult to distinguish them from those of rapid crypt regeneration because of the absence of significant lymphocytic infiltration.
Discussion
We identified 16 patients with pathological evidence of intestinal TMA. It is worth noting that 14 of these patients showed multifactorial post-BMT TMA (grades II-IV) and most of them experienced acute GVHD before the onset of TMA. Endoscopic features of the intestine included edematous mucosa, erythema, multiple ulcers and spontaneous bleeding, which was similar to the findings for GVHD. However, histological findings made differential diagnosis from gut GVHD possible. In addition, the areas of histologic hemorrhage provided evidence of the existence of capillary platelet thrombi that contained GPIIbIIIa(CD41a) and vWF, representing histologic evidence of gut microangiopathy. For two patients who did not meet the clinical criteria of TMA, the pathological diagnosis of TMA could be made by means of colonoscopic biopsies. These results emphasize the significance of histological examination for differential diagnosis of intestinal TMA from acute GVHD for patients with diarrhea after BMT. Acute GVHD and intestinal infection are thought to be the most common causes of diarrhea after the resolution of regimen-related gut toxicity and produce similar clinical symptoms, including lower abdominal pain, profuse diarrhea and intestinal bleeding. [23] [24] [25] [26] [27] [28] [29] [30] We found that the intestinal tract is a prevalent site for post-BMT TMA and that ischemic enterocolitis due to microangiopathy is another mimic of gut GVHD. Although the clinical symptoms of intestinal TMA are similar to those caused by gut GVHD, the distinction between intestinal TMA and gut GVHD is particularly important for clinical procedures. Thus, the involvement of TMA in the gut as one of the targets for acute GVHD clearly indicates the need for substantial revision of current strategies for the diagnosis and treatment of acute GVHD.
It has been reported that multifactorial TMA is associated with high mortality.
1,2 The patients in our study suffered from various complications such as VOD, encephalopathy and hemorrhagic cystitis, and 13 (81%) of the 16 patients died. TMA may affect a multiplicity of organs besides the intestinal tract. Severe diarrhea induces the loss of albumin and immunoglobulin, so that patients with diarrhea may have a higher incidence of lifethreatening infection than those without.
The immunosuppressive drugs CsA and glucocorticoids (GCs) reportedly have adverse effects on endothelial cells and platelets. [31] [32] [33] [34] [35] [36] CsA inhibits the ability of cultured human endothelial cells to produce prostacyclin (PGI 2 ) in response to arachidonic acid, thrombin or calcium ionophores. 31 Endothelial cell-dependent protein C activation decreases as a result of treatment with CsA, 32 and CsA nephrotoxicity causes an increase in plasma thrombomodulin levels as an indicator of vascular injury. 33 In the case of platelets, CsA directly increases the aggregation of normal platelets in response to adenosine diphosphate or epinephrine. 34 GCs also block endothelial cell production and the release of the vasodilators prostaglandin (PGE 2 ) and PGI 2 . 35 The administration of GCs to thrombocytopenic rabbits resulted in a dose-dependent shortening of the bleeding time, which may be caused by the inhibition of endothelial PGI 2 production and consequent augmentation of platelet aggregation. 36 FK506 may also have similar effects, so that the prolonged administration of these agents may result in an increased risk of TMA. Indeed, it has been reported that CsA and FK506 are associated with TMA.
14, 37 Our results showed that prompt tapering off of these immunosuppressants resulted in the resolution of the gut symptoms and long survival in some of these patients.
On the other hand, chronic GVHD is a common late complication of allogeneic BMT and worsens the post transplant prognosis. 38 Since two of our cases died of progressive chronic GVHD after the tapering off of immunosuppressive agents, careful attentions should be paid to the occurrence or progression of chronic GVHD after the reduction of immunosuppressants. An exact effect of the reduction of immunosuppressants for the treatment of TMA should be determined in a prospective study with a substantially larger number of subjects.
